PMID- 36894899
OWN - NLM
STAT- MEDLINE
DCOM- 20230313
LR  - 20230313
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Mar 9
TI  - Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic 
      alterations difference in colorectal Cancer.
PG  - 221
LID - 10.1186/s12885-023-10610-1 [doi]
LID - 221
AB  - BACKGROUND: Large-scale genomic alterations, especially CD274/PD-L1 gene 
      amplification, have great impact on anti-PD-1 efficacy on cancers such as 
      Hodgkin's lymphoma. However, the prevalence of PD-L1 genetic alterations in 
      colorectal cancer (CRC) and its correlation with the tumor immune 
      microenvironment and clinical implications remain unknown. MATERIALS AND METHODS: 
      PD-L1 genetic alterations were evaluated in 324 patients with newly diagnosed CRC 
      including 160 mismatch repair-deficient (dMMR) patients and 164 mismatch 
      repair-proficient (pMMR) patients using fluorescence in situ hybridization (FISH) 
      method. The correlation between PD-L1 and the expression of the common immune 
      markers was analyzed. RESULTS: Totally 33 (10.2%) patients were identified with 
      aberrant PD-L1 genetic alternations including deletion (2.2%), polysomy (4.9%), 
      and amplification (3.1%); They had more aggressive features such as advanced 
      stage (P = 0.02), shorter overall survival (OS) (P < 0.001) than patients with 
      disomy. The aberrations correlated with positive lymph node (PLN) (p = 0.001), 
      PD-L1 expression by immunohistochemistry (IHC) in tumor cells (TCs) or 
      tumor-infiltrated immunocytes (ICs) (both p < 0.001), and pMMR (p = 0.029). When 
      dMMR and pMMR were analyzed independently, the correlations of aberrant PD-L1 
      genetic alterations with PD-1 expression (p = 0.016), CD4 + T cells (p = 0.032), 
      CD8 T + cells (p = 0.032) and CD68 + cells (p = 0.04) were only found in dMMR 
      cohort. CONCLUSIONS: The prevalence of PD-L1 genetic alterations was relatively 
      low in CRC, but the aberrations usually correlate with aggressive nature. The 
      correlation between PD-L1 genetic alterations and tumor immune features was only 
      observed in dMMR CRC.
CI  - (c) 2023. The Author(s).
FAU - Yang, Lin
AU  - Yang L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      1838 Baiyun Avenue North, Guangzhou, 510515, China.
FAU - Liu, Shousheng
AU  - Liu S
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Centre 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road 
      east, Guangzhou, 510060, China.
AD  - Department of General Medicine, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road east, Guangzhou, 510060, China.
FAU - He, Wenzhuo
AU  - He W
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Centre 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road 
      east, Guangzhou, 510060, China.
AD  - Department of General Medicine, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road east, Guangzhou, 510060, China.
FAU - Xiong, Zhenchong
AU  - Xiong Z
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Centre 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road 
      east, Guangzhou, 510060, China. xiongzhch@sysucc.org.cn.
AD  - Department of Breast Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng 
      Road east, Guangzhou, 510060, China. xiongzhch@sysucc.org.cn.
FAU - Xia, Liangping
AU  - Xia L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Centre 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road 
      east, Guangzhou, 510060, China. xialp@sysucc.org.cn.
AD  - Department of General Medicine, Sun Yat-sen University Cancer Center, 651 
      Dongfeng Road east, Guangzhou, 510060, China. xialp@sysucc.org.cn.
LA  - eng
GR  - 82002557/National Natural Science Foundation of China/
GR  - 82102995/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230309
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - Turcot syndrome
SB  - IM
MH  - Humans
MH  - *B7-H1 Antigen/genetics/metabolism
MH  - Tumor Microenvironment/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Prevalence
MH  - *Colorectal Neoplasms/epidemiology/genetics
MH  - DNA Mismatch Repair/genetics
PMC - PMC9996909
OTO - NOTNLM
OT  - Fluorescence in situ hybridization
OT  - Immune microenvironment
OT  - Mismatch repair deficiency
OT  - PD-L1
OT  - Prognosis
COIS- The authors have no conflict of interest to declare.
EDAT- 2023/03/10 06:00
MHDA- 2023/03/14 06:00
PMCR- 2023/03/09
CRDT- 2023/03/09 23:34
PHST- 2022/09/20 00:00 [received]
PHST- 2023/02/06 00:00 [accepted]
PHST- 2023/03/09 23:34 [entrez]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/14 06:00 [medline]
PHST- 2023/03/09 00:00 [pmc-release]
AID - 10.1186/s12885-023-10610-1 [pii]
AID - 10610 [pii]
AID - 10.1186/s12885-023-10610-1 [doi]
PST - epublish
SO  - BMC Cancer. 2023 Mar 9;23(1):221. doi: 10.1186/s12885-023-10610-1.